Need Assistance?
  • US & Canada:
    +
  • UK: +

QL9

* Please kindly note that our products are not to be used for therapeutic purposes and cannot be sold to patients.

QL9 (QLSPFPFDL), derived from the enzyme 2-oxoglutarate dehydrogenase, is a high-affinity alloantigen for the 2C T cell receptor (TCR).

Category
Peptide Inhibitors
Catalog number
BAT-010613
CAS number
159646-83-0
Molecular Formula
C52H74N10O14
Molecular Weight
1063.21
QL9
IUPAC Name
(2S)-2-[[(2S)-3-carboxy-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2,5-diamino-5-oxopentanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoyl]amino]propanoyl]amino]-4-methylpentanoic acid
Synonyms
L-Leucine, L-glutaminyl-L-leucyl-L-seryl-L-prolyl-L-phenylalanyl-L-prolyl-L-phenylalanyl-L-α-aspartyl-; Gln-Leu-Ser-Pro-Phe-Pro-Phe-Asp-Leu; QL 9; QL-9
Appearance
Powder
Purity
≥95%
Density
1.313±0.06 g/cm3 (Predicted)
Boiling Point
1463.5±65.0°C (Predicted)
Sequence
QLSPFPFDL
Storage
Store at -20°C
Solubility
Soluble in Water, DMSO
InChI
InChI=1S/C52H74N10O14/c1-29(2)23-34(55-44(67)33(53)19-20-42(54)64)45(68)60-39(28-63)51(74)62-22-12-18-41(62)49(72)58-37(26-32-15-9-6-10-16-32)50(73)61-21-11-17-40(61)48(71)57-35(25-31-13-7-5-8-14-31)46(69)56-36(27-43(65)66)47(70)59-38(52(75)76)24-30(3)4/h5-10,13-16,29-30,33-41,63H,11-12,17-28,53H2,1-4H3,(H2,54,64)(H,55,67)(H,56,69)(H,57,71)(H,58,72)(H,59,70)(H,60,68)(H,65,66)(H,75,76)/t33-,34-,35-,36-,37-,38-,39-,40-,41-/m0/s1
InChI Key
LKWGVTVKKKGMDA-JBRKIFEHSA-N
Canonical SMILES
CC(C)CC(C(=O)NC(CO)C(=O)N1CCCC1C(=O)NC(CC2=CC=CC=C2)C(=O)N3CCCC3C(=O)NC(CC4=CC=CC=C4)C(=O)NC(CC(=O)O)C(=O)NC(CC(C)C)C(=O)O)NC(=O)C(CCC(=O)N)N
1. Potentiation of T Cell Stimulatory Activity by Chemical Fixation of a Weak Peptide-MHC Complex
Maria Lomunova, Sojin Choi, Kwangmi Kim, Inkyu Hwang Mol Cells . 2017 Jan;40(1):24-36. doi: 10.14348/molcells.2017.2218.
The stability of peptide-MHC complex (pMHC) is an important factor to shape the fate of peptide-specific T cell immune response, but how it influences on T cell activation process is poorly understood. To better understand that, we investigated various T cell activation events driven by LdMHCI loaded with graded concentrations of P2Ca and QL9 peptides, respectively, with 2C TCR Tg T cells; the binding strength of P2Ca for Ldis measurably weaker than that of QL9, but either peptides in the context of Ldinteract with 2C TCR with a similar strength. When their concentrations required for early T cell activation events, which occur within several minutes to an hour, were concerned, EC50s of QL9 were about 100 folds lower than those of P2Ca, which was expected from their association constants for Ld. When EC50s for late activation events, which takes over several hours to occur, were concerned, the differences grew even larger (> 300 folds), suggesting that, due to weak binding, Ld/P2Ca dissociate from each other more easily to lose its antigenicity in a short time. Accordingly, fixation of Ld/P2Ca with paraformaldehyde resulted in a significant improvement in its immunogenicity. These results imply that binding strength of a peptide for a MHC is a critical factor to determine the duration of pMHC-mediated T cell activation and thus the attainment of productive T cell activation. It is also suggested that paraformaldehyde fixation should be an effective tool to ameliorate the immunogenicity of pMHC with a poor stability.
2. TCR scanning of peptide/MHC through complementary matching of receptor and ligand molecular flexibility
K Christopher Garcia, David M Kranz, William F Hawse, Jaroslav Zajicek, Soumya De, Evgenii L Kovrigin, Alex I Greenwood, Brian M Baker, Linda K Nicholson J Immunol . 2014 Mar 15;192(6):2885-91. doi: 10.4049/jimmunol.1302953.
Although conformational changes in TCRs and peptide Ags presented by MHC protein (pMHC) molecules often occur upon binding, their relationship to intrinsic flexibility and role in ligand selectivity are poorly understood. In this study, we used nuclear magnetic resonance to study TCR-pMHC binding, examining recognition of the QL9/H-2L(d) complex by the 2C TCR. Although the majority of the CDR loops of the 2C TCR rigidify upon binding, the CDR3β loop remains mobile within the TCR-pMHC interface. Remarkably, the region of the QL9 peptide that interfaces with CDR3β is also mobile in the free pMHC and in the TCR-pMHC complex. Determination of conformational exchange kinetics revealed that the motions of CDR3β and QL9 are closely matched. The matching of conformational exchange in the free proteins and its persistence in the complex enhances the thermodynamic and kinetic stability of the TCR-pMHC complex and provides a mechanism for facile binding. We thus propose that matching of structural fluctuations is a component of how TCRs scan among potential ligands for those that can bind with sufficient stability to enable T cell signaling.
3. Potent cytolytic response by a CD8+ CTL clone to multiple peptides from the same protein in association with an allogeneic class I MHC molecule
N Fukusen, Y Sykulev, S Kageyama, I A Papayannopoulos, T J Tsomides, H N Eisen J Immunol . 2001 Mar 1;166(5):3028-34. doi: 10.4049/jimmunol.166.5.3028.
CTL clone 2C recognizes the allogeneic class I MHC molecule L(d) in association with peptides derived from alpha-ketoglutarate dehydrogenase (oxoglutarate dehydrogenase (OGDH)), a ubiquitous intracellular protein. One of these peptides, QLSPFPFDL (QL9), elicits more vigorous cytolytic responses than two previously identified naturally processed peptides with overlapping sequences, LSPFPFDL (p2Ca) and VAITRIEQLSPFPFDL (p2Cb), from OGDH. In this study, we show that QL9 forms a more stable complex with cell surface L(d) than does p2Ca or p2Cb and is processed from the longer, naturally occurring peptide p2Cb by 20S proteosomes in vitro. The N-terminal cyclized pyroglutaminyl QL9 (pyroQL9), a form of QL9 to which it is converted at the low pH used for peptide isolation from tissue extracts, is even more active than QL9 in cytotoxicity assays with 2C CTL. Overall, the results indicate that along with the abundant natural peptides p2Ca and p2Cb, the QL9 and other OGDH peptides of various lengths, sharing a conserved C-terminal sequence, are also processed and presented with L(d) as allogeneic ligands for T cells expressing 2C TCR. All these peptides, each available in a low amount, could act in concert at the cell surface, resulting in a high density of cognate ligands that accounts for the exceptionally potent cytolytic response by 2C CTL.
Online Inquiry
Verification code
Inquiry Basket